Biotech | February 19, 2022
cbdMD becomes first American CBD brand to receive UK validation
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Suvinys Developers will supply dydrogesterone to Jagsonpal Pharma as per the terms and conditions mentioned in the agreement.
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
The brand has added a range of exciting new products especially formulated for oily skin.
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
The agreement also had a permanent safeguard mechanism which can be resorted to in a situation of sudden surge in imports.
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
The insights collected by the app will support the pharmaceutical industry’s efforts to further improve patients’ lives by providing actionable data on patients’ individual experiences
Subscribe To Our Newsletter & Stay Updated
